CD8A and neoplasm: Combining telratolimod with both anti-CTLA-4 and anti-PD-L1 resulted in superior activity against treated and untreated tumours than single agents in B16.F10 melanomas, with both tumours displaying an increase in antigen-specific CD8+ T cells [39].